JohnMullinaxMD
General Surgery • Tampa, FLSurgical Oncology (Other than Breast)
Associate Member, Surgical Oncology Sarcoma Department Immunology Program Surgical Director, Cell Therapy Program H. Lee Moffitt Cancer Center
Overview of Dr. Mullinax
Dr. John Mullinax is a general surgeon in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 10 years. He is one of 91 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 148 doctors at Tampa General Hospital who specialize in General Surgery. He has more than 60 publications and over 500 citings.
Office
12902 USF Magnolia Drive
CSB-6, 6169
Tampa, FL 33612Fax+1 813-745-8337
Education & Training
University of South Florida MorsaniFellowship, Complex General Surgical Oncology, 2014 - 2016- University of South Florida MorsaniResidency, Surgery, 2007 - 2014
National Cancer Institute2010 - 2012- University of South Florida College of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2010 - 2026- American Board of Surgery Surgery
- American Board of Surgery Complex General Surgical Oncology
Awards, Honors, & Recognition
- Resident of the Year Department of Surgery, USF College of Medicine, 2012-2013
Clinical Trials
- REtroperitoneal SArcoma Registry: an International Prospective Initiative Start of enrollment: 2016 Sep 01
- Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma Start of enrollment: 2019 Aug 20
- Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma Start of enrollment: 2019 Sep 27
Publications & Presentations
PubMed
- 8 citationsNeoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma.Casey L Liveringhouse, Russell F Palm, John M Bryant, George Q Yang, Matthew N Mills
International Journal of Radiation Oncology, Biology, Physics. 2023-09-01 - 65 citationsCombination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma.John E. Mullinax, MacLean Hall, Sangeetha Prabhakaran, Jeffrey S. Weber, Nikhil I. Khushalani
Frontiers in Oncology. 2018-03-02 - 21 citationsExpansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.Ahmet M. Aydin, MacLean Hall, Brittany L. Bunch, Holly Branthoover, Zachary Sannasardo
International Immunopharmacology. 2021-02-23
Abstracts/Posters
- Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in LymphomaJohn E Mullinax, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Lymphoma Tumor Microenvironment Influences Toxicity after CD19 CAR T Cell TherapyJohn E Mullinax, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Researchers at Johns Hopkins All Children’s Seek to Adapt Adult Treatments to Fight Pediatric CancersSeptember 6th, 2019
Chemotherapy Approach Avoids Amputation in Sarcoma PatientsMarch 22nd, 2017
Three Nonprofit Organizations Step up to Fund Unique Pediatric Cancer Clinical TrialDecember 26th, 2023
Professional Memberships
- Member
- Member
- Member
- Member
- Member
External Links
- Moffitt Websitehttps://www.moffitt.org/providers/john-mullinax/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
